Brokerages Set UiPath Inc. (NYSE:PATH) Price Target at $27.41

Shares of UiPath Inc. (NYSE:PATH) have been given a consensus rating of “Moderate Buy” by the eighteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $27.41.

A number of equities research analysts have issued reports on the company. KeyCorp began coverage on UiPath in a research report on Monday, April 8th. They set an “overweight” rating and a $27.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price target on shares of UiPath in a research report on Wednesday, March 20th. Wells Fargo & Company boosted their price objective on shares of UiPath from $24.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 14th. Morgan Stanley raised their target price on shares of UiPath from $17.00 to $25.00 and gave the company an “equal weight” rating in a research note on Thursday, March 14th. Finally, Canaccord Genuity Group upped their price target on shares of UiPath from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, March 15th.

UiPath Stock Performance

PATH opened at $19.89 on Friday. UiPath has a 1 year low of $13.30 and a 1 year high of $27.87. The company’s 50 day simple moving average is $21.60 and its 200 day simple moving average is $21.78. The stock has a market capitalization of $11.32 billion, a PE ratio of -117.00 and a beta of 1.01.

UiPath (NYSE:PATH) last announced its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. The company had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. As a group, sell-side analysts expect that UiPath will post -0.04 earnings per share for the current fiscal year.

Insider Buying and Selling at UiPath

In other UiPath news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $22.84, for a total transaction of $365,440.00. Following the completion of the sale, the chief financial officer now owns 87,505 shares in the company, valued at approximately $1,998,614.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 96,000 shares of company stock worth $2,023,440 in the last 90 days. 31.03% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On UiPath

A number of hedge funds have recently bought and sold shares of PATH. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in UiPath by 104.4% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 102,000 shares of the healthcare company’s stock valued at $1,745,000 after purchasing an additional 52,100 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its position in shares of UiPath by 196.8% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 332,715 shares of the healthcare company’s stock worth $5,693,000 after acquiring an additional 220,618 shares in the last quarter. Xponance Inc. grew its position in shares of UiPath by 3.9% in the 3rd quarter. Xponance Inc. now owns 44,846 shares of the healthcare company’s stock worth $767,000 after acquiring an additional 1,694 shares in the last quarter. Raymond James & Associates grew its position in shares of UiPath by 51.0% in the 3rd quarter. Raymond James & Associates now owns 89,534 shares of the healthcare company’s stock worth $1,532,000 after acquiring an additional 30,244 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of UiPath by 0.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,385,317 shares of the healthcare company’s stock worth $40,813,000 after acquiring an additional 15,334 shares in the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.